Francesco Izzo is an expert in Oncology at Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (Italy). As of October 2026, ScienceLeadR ranks Francesco Izzo in the top 1% of experts worldwide for Carcinoma. Francesco Izzo has authored 404 publications, the most recent in 2026, and is an investigator in 12 clinical trials, 5 of them ongoing. SLR score: 1,140 (community average: 125). How the SLR is computed.

LeadR Profile

1 140 ScienceLeadR Reputation 1140
Network Map

Oncology

Subspecialties: Surgery - Medical Imaging - Gastroenterology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2006 - 2026

Source: PubMed

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 404

Citations

Citations: 12 273 1st author: 26 Last author: 55 Unique author: 2


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Tumor Biology and Surgical Margin Patterns in Colorectal Liver Metastases: Association Between KRAS/BRAF Status and Type of Resection Margin-BRAF-KRAS LiverMet Collaborative Group.
PMID 42864778 — margins of excision, neoplasms, liver, tumor burden, neoplasm metastasis
J Laparoendosc Adv Surg Tech A20260
Bipolar needle electrodes for electroporation-based treatments in soft and bone tissues: technical design and implementation.
PMID 42804145 — electrodes, radiology, therapeutics, tissues, electroporation, needles
Radiol Med20260
PIK3CA in Cancer: Structure, Biology, Alterations, and Actionability.
PMID 42738319 — genomics, neoplasms, therapeutics
Cancers (Basel)20260
The unusual first sign of presentation of hepatocellular carcinoma: a rare case report.
PMID 42718515 — radiotherapy, epistaxis, carcinoma, hepatocellular, neoplasms, liver, neoplasm metastasis, therapeutics, sphenoid sinus
Front Oncol20260
Robotic versus laparoscopic liver resection for intrahepatic cholangiocarcinoma in elderly patients: a multicentre propensity-weighted analysis.
PMID 42557486 — mortality, conversion to open surgery, liver, aged, endoscopy, morbidity, postoperative complications, cholangiocarcinoma, intrahepatic cholangiocarcinoma
Surg Endosc20261

Clinical Studies 12

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 6
Phase 2 4
Phase 1/Phase 2 1
Phase 3 1

By status:

Recruiting 5
Completed 3
Unknown 2
Active not recruiting 1
Withdrawn 1

By type:

Interventional 7
Observational 5

By Monocentric/Multicentric:

monocentric 9
multicentric2to4 0
multicentric5to9 3
multicentricup10 0

Main Topics

Cohort/Consortium Investigators 14

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Prospective phase IIb study to evaluate the efficacy of laparoscopic electrochemotherapy in the treatment of locally advanced pancreatic cancer ECT LAPC Laparoscopic
2024-519067-17-00 — pancreatic neoplasms, neoplasms, electrochemotherapy, therapeutics
Phase 2Recruiting2024
Global Evaluation of Cholecystectomy Knowledge and Outcomes
NCT06223061 — bile, gallstones, gallbladder, emergencies, bile ducts, neoplasms, cholecystectomy, gallbladder neoplasms
N/AActive not recruiting2023
Neo adjuvant Chemo and Immunotherapy in the Pre operAtive Treatment of Locally Advanced CholangIOcarciNoma
NCT06341764 — antibodies, immunotherapy, antibodies, monoclonal, therapeutics, cholangiocarcinoma
Phase 2Recruiting2023
Prediction of True Oligo metastatic Disease
NCT05806151 — radiotherapy, lymphocytes, neoplasms, gastrointestinal tract, neoplasm metastasis, radiofrequency ablation, therapeutics, colorectal neoplasms, tissues, t-lymphocytes
N/ARecruiting2023
Unravelling the Impact of Radiofrecuency in Liver Surgery the Key to Decrease Local Recurrence
NCT05492136 — margins of excision, neoplasms, liver, hepatectomy, liver neoplasms, neoplasms, second primary, therapeutics, ischemia
N/ARecruiting2023

LeadR Networks

Main global connection map